Visterra closes $26m Series A, to take flu antibody into clinic
This article was originally published in Scrip
Executive Summary
Fresh off a drug discovery deal with Pfizer, infectious disease-focused Visterra has raised $13 million to complete a $26 million Series A venture financing round to advance VIS410, a broad spectrum monoclonal antibody for the prevention and treatment of seasonal and pandemic influenza, and potentially another drug candidate into clinical development.